OneSource in talks to raise Rs 1,670 crore in pre-listing roundOneSource, a TPG Growth-backed specialty pharma CDMO, is in talks with investors to raise $200 million. The company, formerly Stelis Biopha...
Syngene International Q3 Results: Net profit rises 2% YoY to Rs 112 crore, company revises revenue guidanceThe rise in Q3 profit of Syngene International was led by dedicated centres and development and manufacturing services, even as discovery s...
Syngene Q2 Results: Net profit jumps 14% to Rs 117 croreNet profit before an exceptional item rose 20% YoY to 122 crore. The exceptional item pertains to transaction costs relating to the acquisi...
Strides Pharma to spin off CDMO assets to form a separate unitPharmaceutical company Strides Pharma is planning to demerge its contract development and manufacturing services (CDMO) assets into an asso...
Strides sells arm's manufacturing unit to Syngene International for Rs 702 croreStrides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene ...
Stelis Biopharma receives establishment inspection report from USFDAThis follows the abbreviated quality system inspection technique drug pre-approval on-site inspection specifically conducted by the US Food...
Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabsIn the letter written on May 13, Arun Kumar, Founder and Director of Stelis Biopharma Limited, said that after the prime minister had reque...
Stelis Biopharma gets CDSCO nod to export 50 million doses of Sputnik Light vaccineSputnik Light is a single dose vaccine. Stelis partnered with Russia's sovereign wealth fund RDIF to produce and supply the Russian Sputnik...
RDIF, Stelis Biopharma partner to supply 200 mn doses of Sputnik V vaccineStelis' pact with the Russian Direct Investment Fund (RDIF) follows similar deals struck by Indian pharmaceutical firms Gland Pharma and He...
Strides Pharma Q3 results: Net profit declines 62% to Rs 35 crThe company had posted a net profit of Rs 92.33 crore for the corresponding period of the previous fiscal, Strides Pharma Science said in a...
Former HDFC Bank MD Aditya Puri joins global pharma major Strides Group as advisorPuri, who led HDFC Bank since its inception over 25 years ago, retired in October 2020, after a highly successful career which has made the...
Buy Strides Pharma Science, target price Rs 710: ICICI SecuritiesStrides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 5402.27 Crore) operating in Pha...
Strides Pharma board approves addnl USD 40 mn investment in Stelis BiopharmaThe company's board has approved an additional investment up to a maximum of USD 40 million over a period of 24 months for a controlling st...
Karnataka government clears Himatsingka proposal to invest 1,325 crore along with seven other projectsThis was one of the five greenfield projects the high-level committee headed by chief minister Siddaramaiah cleared on Wednesday.
- Strides arm commences construction of $ 60-million Malaysia plant
Stelis Biopharma, wholly-owned arm of Strides Arcolab, has commenced construction of its Rs 370 crore (USD 60 million) biologics facility a...
Strides Arcolab sells 25.1% stake in arm to GMS Holdings; stock upStrides has so far invested $16.9 million in Stelis. The duo will invest $61.9 million taking total equity investment in Stelis to $78.8 mi...
Stelis Biopharma, Pieris AG join hand for drug developmentStelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, said it has entered into a long-term agreement with Germany's Pieris...